Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Multicenter, Open-label, Randomized, Controlled, Parallel Arms Clinical Study on Performance of SGM-101, a Fluorochrome-labeled Anti-CEA Monoclonal Antibody, for Delineation of Primary/Recurrent Tumor and Metastases in Patients Undergoing Surgery for Colorectal Cancer

Trial Profile

Multicenter, Open-label, Randomized, Controlled, Parallel Arms Clinical Study on Performance of SGM-101, a Fluorochrome-labeled Anti-CEA Monoclonal Antibody, for Delineation of Primary/Recurrent Tumor and Metastases in Patients Undergoing Surgery for Colorectal Cancer

Status: Recruiting
Phase of Trial: Phase III

Latest Information Update: 17 Oct 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs SGM 101 (Primary)
  • Indications Cancer metastases; Colon cancer; Colorectal cancer; Rectal cancer
  • Focus Diagnostic use; Registrational
  • Sponsors SurgiMAb
  • Most Recent Events

    • 17 Oct 2019 According to a SurgiMAb media release, Massachusetts General Hospital, Boston, MA, Abramson Cancer Center of the University of Pennsylvania, Philadelphia, PA,Cleveland Clinic Florida, Weston, FL, and Moores Cancer Center UC San Diego Health, La Jolla, CA are the participathing US center.
    • 17 Oct 2019 According to a SurgiMAb media release, first US patient has been recruited. This trial is designed following discussions with the FDA and other regulators.
    • 19 Jul 2019 Planned End Date changed from 1 Dec 2019 to 1 Dec 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top